Search
NGD-4715
go.drugbank.com/drugs/DB06027ExperimentalNGD-4715 is an investigational compound developed for the treatment of Obesity. NGD-4715 functions as a melanin-concentrating hormone receptor 1 antagonist.
Urethane
go.drugbank.com/drugs/DB04827ApprovedWithdrawnUrethane, formerly marketed as an inactive ingredient in Profenil injection, was determined to be carcinogenic and was removed from the Canadian, US, and UK markets in 1963.
Calcium lactate gluconate
go.drugbank.com/drugs/DB13365InvestigationalMixtures: Calcium Vitamin D3 STELLA Effervescent tabletATN-161
go.drugbank.com/drugs/DB05491InvestigationalIt inhibits the migration and adhesion of particular integrins on activated endothelial cells that play a critical role in tumor angiogenesis. … This approach targeting both the tumor vasculature and the cancer cells themselves, may be effective in single therapy as well as combination therapy.
GTS-21
go.drugbank.com/drugs/DB05708Investigationalrelated and memory related tasks (Kitagawa, et al. … GTS-21 has been studied in multiple Phase I studies in healthy volunteers and one Phase I/II study in schizophrenic patients. In all studies, the compound was well tolerated.
Affitope AD01
go.drugbank.com/drugs/DB06086InvestigationalAffitope AD01 is an investigational drug developed for immunization to treat Alzheimer's Disease. … AD01 is a short peptide (7 amino acids in length) that induces Aß-targeting antibodies, therefore lowering Aß aggregates.
Indole-3-carbinol
go.drugbank.com/drugs/DB12881InvestigationalIndole 3 Carbinol is under investigation in clinical trial NCT00033345 (Indole-3-Carbinol in Preventing Breast Cancer in Nonsmoking Women Who Are at High Risk For Breast Cancer).
Categories: Compounds used in a research, industrial, or household settingAdrafinil
go.drugbank.com/drugs/DB08925ApprovedWithdrawnIt was marketed in France and elsewhere in Europe under the trade name Olmifon until September 2011 when France's FDA equivalent reassessed the drug and withdrew marketing permission. … Adrafinil does not currently have FDA approval and is thus unregulated in the United States.
Clinafloxacin
go.drugbank.com/drugs/DB14025ExperimentalHowever, its approval and release have been halted due to the presence of serious side effects.
OSI-930
go.drugbank.com/drugs/DB05913InvestigationalIn preclinical studies, OSI-930 shows broad efficacy in tumor models representative of small cell lung cancer, glioblastoma, colorectal, renal, head and neck, non-small cell lung cancer and gastric cancers … OSI-930 is designed to target both cancer cell proliferation and blood vessel growth (angiogenesis) in selected tumors.